BOCA RATON, Fla., Sept. 29, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered into a licensing agreement with Impopharma, Inc. to commercialize a generic version of a leading corticosteroid product with generic sales in excess of $25M. Impopharma is the manufacturer of the ANDA, which will be marketed exclusively by Breckenridge for the U.S. market. The product ANDA has been filed and is pending final approval by the U.S. Food and Drug Administration.
Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com
Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, dermal products. Please visit www.impopharma.com.
SOURCE Breckenridge Pharmaceutical, Inc.